Navigation Links
3SBio Inc. Announces Unaudited Second Quarter Results
Date:8/17/2010

3SBio Inc. Announces Unaudited Second Quarter Results -- re> SHENYANG, China, Aug. 17 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Earnings Forecasts & Projections, Earnings Click to view news release full screen  

3SBio Inc. Announces Unaudited Second Quarter Results

 

SHENYANG, China, Aug. 17 /PRNewswire-Asia-FirstCall/ -- -- 2Q revenues grew 29.5% Y-o-Y to RMB105.5 million (US$15.6million) -- 1H revenues grew 34.5% Y-o-Y to RMB201.9 million (US$29.8 million) -- Company reiterates FY2010 revenue guidance -- New plant is granted GMP certification by SFDA

3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China- based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the second quarter ended June 30, 2010.

Second Quarter 2010 Financial Highlights: -- Total net revenues increased by 29.5% over the second quarter of 2009 to RMB105.5 million (US$15.6 million). -- Operating income increased by 8.2% over the second quarter of 2009 to RMB27.9 million (US$4.1 million). -- Net income decreased by 5.4% over the second quarter of 2009 to RMB25.5 million (US$3.8 million) on a GAAP basis, and increased by 0.6% over the second quarter of 2009 to RMB25.5 million (US$3.8 million) on a non-GAAP basis. -- Net income per American Depositary Share ("ADS") on a fully-diluted basis for the second quarter of 2010 was RMB1.16 (US$0.17) compared with RMB1.25 (US$0.18) for the second quarter of 2009 on a GAAP basis, and RMB1.16 (US$0.17) for the second quarter of 2010 compared with RMB1.18 (US$0.17) for the second quarter of 2009 on a non-GAAP basis. First Half 2010 Financial Highlights: -- Total net revenues in the first half of 2010 increased by 34.5% to RMB201.9 million (US$29.8 million) compared to RMB150.1 million (US$22.0 million) in the first half of 2009. -- Operating income increased by 22.3% over the first half of 2009 to RMB56.1 million (US$8.3 million). -- Net income increased by 21.7% over the first half of 2009 to RMB52.2 million (US$7.7 million) on a GAAP basis, and increased by 13.7% over the first half of 2009 to RMB52.2 million (US$7.7 million) on a non-GAAP basis. -- Net income per ADS on a fully-diluted basis for the first half of 2010 was RMB2.37 (US$0.35) compared with RMB1.99 (US$0.29) for the first half of 2009 on a GAAP basis, and RMB2.37 (US$0.35) for the first half of 2010 compared with RMB2.13 (US$0.31) for the first half of 2009 on a non-GAAP basis. Second Quarter 2010 Business Highlights -- EPIAO, the Company's flagship injectable recombinant human erythropoietin ("EPO") product, demonstrated strong growth with net revenues from EPIAO in the second quarter of 2010 rising 22.9% to RMB62.8 million (US$9.3 million) compared to RMB51.1 million (US$7.5 million) in the second quarter of 2009. EPIAO accounted for 59.5% of total revenues in the second quarter of 2010, compared to 62.7% in the same period of 2009. According to the latest data from IMS Health China, EPIAO's market share in terms of value reached 43.3% in the first quarter of 2010. -- Net revenues for TPIAO, the Company's novel recombinant human thrombopoietin ("TPO") product, increased by 44.6% to RMB32.1 million (US$4.7 million) in the second quarter of 2010, compared to RMB22.2 million (US$3.3 million) in the second quarter of 2009. TPIAO accounted for 30.5% of total revenues in the second quarter of 2010 compared to 27.3% in the same period of 2009. -- Iron Sucrose sales grew 51.1% in the second quarter to RMB4.5 million (US$0.7 million), accounting for 4.2% of total revenues, compared to 3.6% in the second quarter of 2009. While still a relatively small share of total revenues, the strong growth validates our strategy of introducing new products that are complementary to our core nephrology franchise. -- Two novel research products, Feraheme, an IV iron product from AMAG Pharmaceuticals, and NuPIAO, our long-lasting second generation erythropoietin product, are waiting for approval to enter clinical phase III and phase I, respectively. 3SBio continues to work with the State Food and Drug Administration ("SFDA") to advance the regulatory approval of the three new product programs submitted in 2008. The 36,000 IU dosage formulation of EPIAO and the TPIAO label extension for the treatment of ITP are now pending manufacturing license approval, while Nuleusin, a treatment for late stage metastatic renal cell carcinoma, is still under review. Events Subsequent to June 30, 2010 Following the completion of construction of the new EPIAO and TPIAO plant in the first quarter, the SFDA granted Good Manufacturing Practice ("GMP") certification in August 2010. GMP certification will support the future growth of EPIAO and TPIAO in China and serve as an important step towards exploring global biosimilar opportunities. -- Dr. Jing Lou, chief executive officer of 3SBio, commented: "Overall, the business is performing as expected with a strong set of results this quarter and first half and we reiterate our full-year revenue guidance of US$56-60 million. EPIAO's market share by value in the first quarter of 2010 reached an all-time high of 43.3% and for the first time, TPIAO sales accounted for more than 30% of net revenues, providing further evidence that we are successfully diversifying our product mix. We are also pleased to announce that our new EPIAO and TPIAO plant was inspected by the SFDA in July and has been formally certified as GMP compliant. This is a significant milestone for us as we focus on growing our business in China while taking important steps towards exploring global biosimilar opportunities. "

Three months ended June 30, 2010 Unaudited Financial Results

Net revenues. Net revenues increased by 29.5% to RMB105.5 million (US$15.6 million) for the second quarter of 2010 from RMB81.5 million (US$11.9 million) for the same period in 2009. This increase was largely due to continued strength from EPIAO and TPIAO products which increased by 22.9% and 44.6%, respectively, over the same period in 2009. TPIAO remained the Company's second largest revenue contributor in the quarter, accounting for 30.5% of total net revenues. Export sales declined by 16.9% to RMB2.9 million (US$0.4 million), and revenues from our IV Iron Sucrose supplement rose 51.1% to RMB4.5 million (US$0.7 million).

Gross profit. As a result of continued sales growth from key products, gross profit for the second quarter of 2010 increased by 26.4% to RMB94.8 million (US$14.0 million) from RMB75.0 million (US$11.0 million) for the same period in 2009. Gross margin decreased by 2.2% to 89.8% for the second quarter of 2010 from 92.0% for the same period in 2009. The decrease in gross margin is mainly due to higher depreciation charges attributable to the new production facilities in Shenyang.

Operating expenses. Operating expenses were RMB66.8 million (US$9.9 million) for the second quarter of 2010, or 63.4% of net revenues, compared to operating expenses of RMB49.2 million (US$7.2 million), or 60.3% of net revenue for the same period in 2009. The increase in operating expenses as a percentage of net revenues was largely driven by higher SG&A expenses.

-- Research and development ("R&D") costs. R&D costs for the second quarter of 2010 were RMB5.7 million (US$0.8 million), or 5.4% of net revenues, compared to RMB4.3 million (US$0.6 million), or 5.2% of net revenues for the same period in 2009. -- Sales, marketing and distribution expense. Sales, marketing and distribution expenses for the second quarter of 2010 were RMB47.6 million (US$7.0 million), or 45.1% of net revenues, compared to RMB36.2 million (US$5.3 million), or 44.5% of net revenue, for the same period in 2009. The increase was primarily attributable to higher sales activities in general and continued investment in building the TPIAO and EPIAO brands. -- General and administrative expenses. General and administrative expenses for the second quarter of 2010 were RMB13.5 million (US$2.0 million), or 12.8% of net revenues representing an increase of 56.0% from general and administrative expenses of RMB8.7 million (US$1.3 million), or 10.6% of net revenues for the same period in 2009.

Operating income. Operating income was RMB27.9 million (US$4.1 million) for the second quarter of 2010, an increase of 8.2% from operating income of RMB25.8 million (US$3.8 million) for the same period in 2009. Operating margin for the second quarter of 2010 was 26.5% as compared to 31.7% for the same period in 2009.

Interest income. The Company recorded net interest income of RMB2.4 million (US$0.3 million) for the second quarter of 2010, compared to RMB2.5 million (US$0.4 million) for the same period in 2009.

Net income. GAAP net income was RMB25.5 million (US$3.8 million) for the second quarter of 2010, 5.4% lower than net income of RMB27.0 million (US$0.4 million) for the same period in 2009. GAAP net income per ADS on a fully- diluted basis for the second quarter of 2010 increased to RMB1.16 (US$0.17) from RMB1.25 (US$0.18) for the same period in 2009. GAAP net margin for the second quarter of 2010 was 24.2% as compared to 33.1% for the same period in 2009.

Non-GAAP net income for the second quarter of 2010 was RMB25.5 million (US$3.8 million), 0.6% higher than non-GAAP net income of RMB25.4 million (US$3.7 million) for the same period in 2009.

Non-GAAP net income per ADS on a fully-diluted basis for the second quarter of 2010 decreased to RMB1.16 (US$0.17) from RMB1.18 (US$0.17) for the same period in 2009. Non-GAAP net margin for the second quarter of 2010 was 24.2% as compared to 31.1% for the same period in 2009.

Six months ended June 30, 2010 Unaudited Financial Results

Net revenues. Net revenues for the first half of 2010 increased by 34.5% to RMB201.9 million (US$29.8 million), from RMB150.1 million (US$22.0 million) for the same period in 2009. The increase was primarily attributable to increased sales from our EPIAO and TPIAO products, underpinned by continued strong demand in the oncology and nephrology markets.

Net revenues from EPIAO for the first half of 2010 increased by 27.7% to RMB120.0 million (US$17.7 million) from RMB94.0 million (US$13.8 million) for same period in 2009. Net revenues from TPIAO in the first half of 2010 increased by 51.8% to RMB62.1 million (US$9.2 million) from RMB41.0 million (US$6.0 million) for the same period in 2009. In addition, revenue from our export business was RMB6.0 million (US$0.9 million), representing a decrease of 12.7% over the first half of 2009, while revenue from our IV Iron Sucrose supplement was RMB8.6 million (US$1.3 million), representing an increase of 71.6% over the first half of 2009.

Gross profit. Gross profit for the first half of 2010 increased by 33.2% to RMB183.3 million (US$27.0 million) from RMB137.6 million (US$20.1 million) for the same period in 2009. Gross margin decreased by 0.9% to 90.8% for the first half month months of 2010 from 91.7% for the same period in 2009.

Operating income. For the first half ended June 30, 2010, operating income increased by 22.3% to RMB56.1 million (US$8.3 million), compared to RMB45.9 million (US$6.7 million) for the same period in 2009. Operating margin for the first half ended June 30, 2010 was 27.8% as compared to 30.6% for the half months ended June 30, 2010.

Net income. GAAP net income for the first half of 2010 increased by 21.7% to RMB52.2 million (US$7.7 million) compared with RMB42.9 million (US$6.3 million) for the same period in 2009. GAAP net margin for the first half ended June 30, 2010 was 25.8% as compared to 28.6% for the same period in 2009. GAAP net income per ADS on a fully-diluted basis for the first half of 2010 increased to RMB2.37 (US$0.35) from RMB1.99 (US$0.29) for the same period in 2009.

Non-GAAP net income for the first half of 2010 increased by 13.7% to RMB52.2 million (US$7.7 million) compared with RMB45.9 million (US$6.7 million) for the same period in 2009. Non-GAAP net margin for the first half ended June 30, 2010 was 25.8% as compared to 30.6% for the same period in 2009. Non-GAAP net income per ADS for the first half of 2010 increased to RMB2.37 (US$0.35) from RMB 2.13 (US$0.31) for the same period in 2009.

Cash and cash equivalents / Time deposits. 3SBio had positive operating cash flows of RMB34.3 million (US$5.1 million) for the second quarter 2010, and as of June 30, 2010 retained a strong balance sheet with cash, cash equivalents, restricted cash and time deposits of RMB749.3 million (US$110.5 million), a 0.1% increase from RMB740.5 million (US$108.5 million) as of December 31, 2009.

2010 Full Year Guidance

Based on current market conditions and visibility provided during the second quarter, the Company reiterates its total net revenue target for the full year of 2010 of between US$56 million to US$60 million, resulting in a year-over-year increase of approximately 21% to 29%.

Conference Call

3SBio's senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 8:00 pm (Beijing/Hong Kong) on August 18, 2010 to discuss its 2010 second quarter financial results and recent business activity. The conference call may be accessed using the dial-in numbers below:

Conference ID: 92606068 Local dial-in: China landline 800-819-0121 China mobile 400-620-8038 Hong Kong 852-2475-0994 International toll-free dial-in: Hong Kong 800930346 United Kingdom 080-8234-6646 United States 1-866-519-4004 International toll dial-in: 65 6723 9381 Replay- Conference ID: 92606068 A telephone replay will be available two hours after the call until August 24, 2010, at: International dial-in: 61-2-8235-5000 United States dial-in: 1-866-214-5335

Webcast

A live webcast of the conference will be available on the investor relations page of 3SBio's website at http://bbs.3sbio.com/en/News/xinvestors.aspx and at http://tinyurl.com/3SBio2010Q2 .

A replay of the webcast will be available within one hour after the conclusion of the call.

Non-GAAP Financial Measures: Reconciliation of GAAP to Non-GAAP

To supplement the Company's financial information presented in accordance with general accepted accounting principles ("GAAP"), the Company has utilized some non-GAAP financial measures to provide investors and management with supplemental measures that facilitate comparisons of operating performance and trends with prior and future operating performance, and that may not otherwise be apparent on a GAAP basis. These non-GAAP financial measures include non- GAAP net income, non-GAAP net income per share, and non-GAAP net income per ADS. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principals, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. These measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures. Please see the attached reconciliation of GAAP to non-GAAP for an explanation of the amounts excluded to arrive at non-GAAP financial measures for the three-month periods ended June 30, 2009 and June 30, 2010 and for the half month periods ended June 30, 2009 and June 30, 2010.

Statement Regarding Unaudited Financial Information

The unaudited financial information set forth above is preliminary and subject to adjustments and modifications. The audited financial statements and related notes are to be included in our annual report on Form 20-F for the year ending December 31, 2010. Adjustments and modifications to the financial statements may be identified during the course of the audit work, which could result in significant differences from this preliminary unaudited financial information.

Currency Convenience Translation

For the convenience of readers, certain RMB amounts have been translated into US dollars at the rate of RMB6.7815 to US$1.00, the noon buying rate for US dollars in effect on June 30, 2010 for cable transfers of RMB per US dollar as certified for customs purposes by the Federal Reserve Bank of New York. A rate of 6.8302 was used for comparative purposes as of June 30, 2009.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com .

Safe Harbor Statement

Certain statements in the disclosures of 3SBio, Inc. (the "Company" or "3SBio") for the second quarter of fiscal 2010 ("Disclosures") that are not purely historical in nature may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Disclosures include the press release, the conference call and any accompanying materials, and any other information issued, released or publicized by the Company with respect to fiscal 2010 and the second quarter.

These forward-looking statements address activities, events, conditions, or developments that we currently expect or anticipate may occur in the future, and include, but may not be limited to, discussions and statements regarding revenue guidance; product development; impact of the government policies and regulation; regulatory approval process; regulatory action as to product pricing; timing of plant certification and production launch; export growth and expansion; product demands; production capacity; capital expense estimate; and future operations and strategies. Forward-looking statements can be identified by such terminology as "believe," "expect," "plans," "strategy," "potential", "prospects," "forecast," "estimate," "project," "anticipate," "aim," "will" or "would", "may" or "might", and words, phrases, expressions, and usages of similar meaning or substance or the negative of such words, phrases, expressions and usages.

Forward-looking statements are based on management's current assumptions, beliefs, expectations, and projections, in light of the information currently available to it, and actual results, performances, or achievements could differ materially from those implied or expressed by the forward-looking statements. Among the factors that could cause 3SBio's actual results to differ from what the Company currently anticipates may include changes in the healthcare industry in PRC, including changes in the healthcare policies, regulations, and regulatory practice, and changes in the healthcare insurance system; competition from other domestic and foreign pharmaceutical companies; market growth for pharmaceutical products in China; the completion of 3SBio's ongoing clinical trials as planned; receipt and timing of regulatory approvals for 3SBio's products; receipt and timing of regulatory certifications; products inclusion in government reimbursement; 3SBio's ability to expand its production, sales and distribution network and other aspects of its operations; effects of partnerships and acquisitions; market acceptance of 3SBio products; actual hospital or patient demand for our products; ability to effectively protect our intellectual properties; and fluctuations in general economic and business conditions in China.

For additional information on factors identified above and other risk factors, uncertainties and assumptions that may affect 3SBio's business, financial conditions and results of operations, please refer to the Company's filings with the Securities and Exchange Commission at http://www.sec.gov , and, in particular, "Introduction - Cautionary Statement concerning Forward Looking Statements", Item 3.D "Risk Factors", Item 5. "Operating and Financial Review and Prospects", and other applicable discussions in 3SBio's annual report on Form 20-F for the year ended December 31, 2009.

All the statements in the Disclosures speak as of the date of the initial release, even if subsequently made available on the 3SBio website or otherwise. 3SBio undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, subsequent events or otherwise, after the date of this press release.

For more information, please contact: Investor Contacts Bo Tan Chief Financial Officer 3SBio Inc. Phone: +86-24-2581-1820 Email: ir@3SBio.com Tom Folinsbee Director of Investor Relations 3SBio Inc. Phone: +852-8191-6991 Email: ir@3SBio.com 3SBio Inc. Unaudited consolidated balance sheets (expressed in thousands) December 31, June 30, June 30, 2009 2010 2010 RMB RMB US$ (audited) (unaudited)(unaudited) Assets Current assets Cash and cash equivalents 262,767 145,637 21,476 Restricted cash 9,300 661 97 Time deposits with financial institutions 468,451 602,948 88,911 Notes receivable 31,265 38,259 5,642 Accounts receivable, less allowance for doubtful accounts: December 31, 2009 - RMB2,915; June 30, 2010 - RMB2,695 (US$397) 54,661 80,037 11,802 Inventories 15,406 17,820 2,628 Prepaid expenses and other receivables 8,705 16,029 2,364 Deferred tax assets 2,079 2,106 311 Total current assets 852,634 903,497 133,231 Available-for-sale securities 11,407 11,570 1,706 Long-term equity investment -- 1,874 276 Property, plant and equipment, net 165,120 181,931 26,828 Lease prepayments 8,541 8,364 1,233 Non-current deposits 10,067 8,112 1,196 Intangible assets, net 4,125 3,575 527 Long term receivable -- 3,352 494 Deferred tax assets 1,567 2,516 371 Total assets 1,053,461 1,124,791 165,862 Liabilities Current liabilities Accounts payable 2,736 3,080 454 Deferred grant income 374 374 55 Accrued expenses and other payables 33,421 38,198 5,633 Income tax payable 1,914 4,117 607 Total current liabilities 38,445 45,769 6,749 Deferred grant income 2,778 2,590 382 Total liabilities 41,223 48,359 7,131 Commitments and contingencies -- -- -- Shareholders' equity Share capital -ordinary shares US$0.0001 par value, 500,000,000 shares authorized, 150,641,461 and 151,053,710 issued and outstanding as of December 31, 2009 and June 30, 2010, respectively 121 121 18 Additional paid-in capital 915,267 929,144 137,012 Accumulated other comprehensive loss (100,608) (102,466) (15,110) Retained earnings 197,458 249,633 36,811 Total shareholders' equity 1,012,238 1,076,432 158,731 Total liabilities and shareholders' equity 1,053,461 1,124,791 165,862 3SBio Inc. Unaudited quarterly consolidated statements of income (expressed in thousands, except per share , per ADS and other share and ADS data) For the Three For the Three Months Ended Months Ended June 30, 2009 June 30, 2010 RMB US$ RMB US$ (unaudited) (unaudited) (unaudited) (unaudited) Net Revenues: EPIAO 51,081 7,479 62,797 9,260 TPIAO 22,217 3,253 32,135 4,739 Intefen 1,289 189 1,236 182 Inleusin 425 62 500 74 Iron sulcrose 2,951 432 4,459 658 Export 3,520 515 2,926 431 Others -- -- 1,439 212 Total net revenues 81,483 11,930 105,492 15,556 Cost of revenues (6,518) (954) (10,734) (1,583) Gross profit 74,965 10,976 94,758 13,973 Operating expenses Research and development costs (4,252) (623) (5,741) (847) Sales, marketing and distribution expenses (36,242) (5,306) (47,585) (7,017) General and administrative expenses (8,662) (1,268) (13,516) (1,993) Total operating expenses (49,156) (7,197) (66,842) (9,857) Operating income 25,809 3,779 27,916 4,116 Other income Interest income 2,454 359 2,357 348 Grant income 93 14 93 14 Net realized gain on available- for-sale securities 1,611 236 -- -- Others 1,681 246 881 130 Total other income 5,839 855 3,331 492 Income before income tax expense 31,648 4,634 31,247 4,608 Income tax expense (4,670) (684) (5,723) (844) Net income 26,978 3,950 25,524 3,764 Net income per share: Basic and diluted 0.18 0.03 0.17 0.02 Basic weighted average number of shares outstanding 150,586,455 150,586,455 150,849,065 150,849,065 Diluted weighted average number of shares outstanding 150,719,313 150,719,313 154,426,639 154,426,639 Net income per ADS: Basic 1.25 0.18 1.18 0.17 Diluted 1.25 0.18 1.16 0.17 Basic weighted average number of ADSs outstanding 21,512,351 21,512,351 21,549,866 21,549,866 Diluted weighted average number of ADSs outstanding 21,531,330 21,512,330 22,060,948 22,060,948 3SBio Inc. Unaudited quarterly consolidated statements of income (expressed in thousands, except per share , per ADS and other share and ADS data) For the Six For the Six Months Ended Months Ended June 30, 2009 June 30, 2010 RMB US$ RMB US$ (unaudited)(unaudited)(unaudited)(unaudited) Net Revenues: EPIAO 93,991 13,761 120,009 17,697 TPIAO 40,927 5,992 62,120 9,160 Intefen 2,555 374 2,573 379 Inleusin 693 101 1,033 152 Iron sulcrose 4,997 732 8,577 1,265 Export 6,851 1,003 5,982 882 Others 67 10 1,574 232 Total net revenues 150,081 21,973 201,868 29,767 Cost of revenues (12,517) (1,833) (18,594) (2,742) Gross profit 137,564 20,140 183,274 27,025 Operating expenses Research and development costs (6,709) (982) (10,423) (1,537) Sales, marketing and distribution expenses (69,191) (10,130) (90,136) (13,291) General and administrative expenses (15,751) (2,306) (26,573) (3,918) Total operating expenses (91,651) (13,418) (127,132) (18,746) Operating income 45,913 6,722 56,142 8,279 Other income /(expenses), net Interest income 6,526 955 5,499 811 Grant income 187 27 187 28 Net realized gain on available-for-sale securities 1,611 236 -- -- Impairment loss on available-for-sale Securities (4,624) (677) -- -- Others 1,339 196 1,032 152 Total other (expenses)/ income, net 5,039 737 6,718 991 Income before income tax expense 50,952 7,459 62,860 9,270 Income tax expense (8,088) (1,184) (10,685) (1,576) Net income 42,864 6,275 52,175 7,694 Net income per share: Basic 0.28 0.04 0.35 0.05 Diluted 0.28 0.04 0.34 0.05 Basic weighted average number of shares outstanding 150,586,455 150,586,455 150,788,700 150,788,700 Diluted weighted average number of shares outstanding 150,694,273 150,694,273 153,878,594 153,878,594 Net income per ADS: Basic 1.99 0.29 2.42 0.36 Diluted 1.99 0.29 2.37 0.35 Basic weighted average number of ADSs outstanding 21,512,351 21,512,351 21,541,243 21,541,243 Diluted weighted average number of ADSs outstanding 21,527,753 21,527,753 21,982,656 21,982,656 Reconciliations of GAAP net income to non-GAAP net income for the first quarter of 2009 and 2010 (in RMB thousands, unaudited) Three months ended Three months ended June 30, 2009 June 30, 2010 GAAP Adjust- Non-GAAP GAAP Adjust- Non-GAAP ment ment RMB US$ RMB RMB US$ RMB US$ RMB RMB US$ Net income 26,978 3,950 (1,611) 25,367 3,714 25,524 3,764 -- 25,524 3,764 The adjustment for the three months ended June 30, 2009 is for the exclusion of the gain of RMB1, 611,000 on disposal of available-for-sale securities. Reconciliations of GAAP net income to non-GAAP net income for the first half of 2009 and 2010 (in RMB thousands, unaudited) Six months ended Six months ended June 30, 2009 June 30, 2010 GAAP Adjust- Non-GAAP GAAP Adjust- Non-GAAP ment ment RMB US$ RMB RMB US$ RMB US$ RMB RMB US$ Net income 42,864 6,275 3,013 45,877 6,716 52,175 7,694 -- 52,175 7,694 The adjustment for the six months ended June 30, 2009 is for the exclusion of the impairment loss of RMB 4,624,000 on available-for-sale securities and gain of RMB1, 611,000 on disposal of available-for-sale securities.
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. 3SBio Inc. Announces Second Quarter 2008 Results
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. 3SBio Inc. Announces Results of Annual General Meeting
5. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
6. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
7. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
8. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
9. 3SBio Inc. Files for SFDA Approval of NuLeusin
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Diego, CA (PRWEB) , ... December 01, 2016 , ... ... data from its Phase I/II clinical trials for AC0010 at the World Conference on ... forward to providing an update on the phase I/II clinical trials for AC0010 in ...
(Date:12/2/2016)... ... 01, 2016 , ... The Conference Forum has announced that the 3rd annual ... place on February 1-3, 2017 at the Roosevelt Hotel in New York City. Led ... a unique 360-degree approach, which addresses the most up-to-date information regarding business aspects, clinical ...
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the Prudential ... December 3rd, 2016. The event, which is held on the United Nations International Day ... with Disabilities back into the workplace. Suitable Technologies is partnering with NTI to showcase ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a brand of ... flexure design that ensures high alignment accuracy by preventing unwanted shaft rotation. The ... where extreme precision is required, such as in medical equipment, laboratory instrumentation, clean ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
Breaking Biology News(10 mins):